Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
作者信息
Di Altobrando A, Patrizi A, Bardazzi F
机构信息
Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.
出版信息
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e295-e297. doi: 10.1111/jdv.16491.
Abstract
摘要
相似文献
1
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是否会影响自身免疫性水疱病的免疫抑制治疗？
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e295-e297. doi: 10.1111/jdv.16491.
2
Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.2019冠状病毒病大流行期间自身免疫性大疱性疾病管理的专家建议。
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e302-e303. doi: 10.1111/jdv.16525. Epub 2020 Jun 4.
3
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.如何在 COVID-19 时代处理自身免疫性风湿和炎症性肠病患者：专家意见。
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
4
Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases.自身免疫性水疱病患者接种新型冠状病毒疫苗的考量
Eur J Dermatol. 2021 Jun 1;31(3):415-417. doi: 10.1684/ejd.2021.4043.
5
Biologics in systemic autoimmune diseases during COVID-19 pandemic.新冠疫情期间系统性自身免疫性疾病中的生物制剂
Clin Rheumatol. 2020 Dec;39(12):3529-3531. doi: 10.1007/s10067-020-05439-z. Epub 2020 Oct 4.
6
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients.意大利东北部自身免疫性风湿病患者的 SARS-CoV-2 感染：对 916 例患者的横断面研究。
J Autoimmun. 2020 Aug;112:102502. doi: 10.1016/j.jaut.2020.102502. Epub 2020 Jun 8.
7
SARS-CoV-2 infection among patients with systemic autoimmune diseases.系统性自身免疫性疾病患者中的 SARS-CoV-2 感染。
Autoimmun Rev. 2020 Jul;19(7):102575. doi: 10.1016/j.autrev.2020.102575. Epub 2020 May 5.
8
COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause.伴有肺部受累的新型冠状病毒肺炎。一种已知病因的自身免疫性疾病。
Reumatol Clin (Engl Ed). 2020 Jul-Aug;16(4):253-254. doi: 10.1016/j.reuma.2020.04.001. Epub 2020 Apr 8.
9
Handling immune-suppressive therapies during SARS-CoV-2 pandemic: insights from pediatric datasets.在新冠疫情期间处理免疫抑制疗法：来自儿科数据集的见解
J Nephrol. 2020 Oct;33(5):883-885. doi: 10.1007/s40620-020-00821-1.
10
[Autoimmune diseases in the context of pandemic COVID-19].[大流行背景下的新冠肺炎相关自身免疫性疾病]
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):827-830.
引用本文的文献
1
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.新冠疫情期间的自身免疫性大疱性疾病：2022年利妥昔单抗与疫苗最新进展
Front Med (Lausanne). 2023 Jan 19;10:1112823. doi: 10.3389/fmed.2023.1112823. eCollection 2023.
2
Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.COVID-19疫情期间的天疱疮：感染风险、疫苗反应及管理策略
J Clin Med. 2022 Jul 8;11(14):3968. doi: 10.3390/jcm11143968.
3
Autoimmune bullous dermatoses associated with COVID-19 outbreak in Russian patients: a single case series.俄罗斯患者中与新冠疫情相关的自身免疫性大疱性皮肤病：单病例系列报道
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e606-e609. doi: 10.1111/jdv.18118. Epub 2022 Apr 22.
4
Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern.鉴定可重新用于对抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其关注变体的广谱抗冠状病毒化学制剂。
Curr Res Virol Sci. 2022;3:100019. doi: 10.1016/j.crviro.2022.100019. Epub 2022 Jan 15.
5
Impact of COVID-19 on autoimmune blistering diseases.COVID-19 对自身免疫性水疱病的影响。
Clin Dermatol. 2021 May-Jun;39(3):359-368. doi: 10.1016/j.clindermatol.2021.01.007. Epub 2021 Feb 2.
6
The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?首剂新冠疫苗可能引发天疱疮和大疱性类天疱疮病情加重：那么第二剂疫苗因此禁忌接种吗？
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e645-e647. doi: 10.1111/jdv.17472. Epub 2021 Jul 13.
7
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?一项全国性多发性硬化症-新冠病毒研究的结果：土耳其多发性硬化症队列揭示了什么？
Mult Scler Relat Disord. 2021 Jul;52:102968. doi: 10.1016/j.msard.2021.102968. Epub 2021 Apr 18.
8
Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.病例报告：用利妥昔单抗治疗的天疱疮患者 COVID-19 后完全快速康复。
Front Immunol. 2021 Apr 16;12:665522. doi: 10.3389/fimmu.2021.665522. eCollection 2021.
9
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.在 2019 冠状病毒病大流行期间及之后，针对炎症性皮肤病患者免疫治疗的实用主义方法的立场声明。
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):797-806. doi: 10.1111/jdv.17075. Epub 2021 Feb 3.
10
Skin manifestations of COVID-19 in children: Part 3.儿童 COVID-19 皮肤表现：第 3 部分。
Clin Exp Dermatol. 2021 Apr;46(3):462-472. doi: 10.1111/ced.14483. Epub 2020 Nov 18.
本文引用的文献
1
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.关于 SARS-CoV-2 感染潜在发病机制的假说——病毒性肺炎患者免疫变化的综述。
Emerg Microbes Infect. 2020 Dec;9(1):727-732. doi: 10.1080/22221751.2020.1746199.
2
What is novel in the clinical management of pemphigus.天疱疮的临床管理有哪些新进展。
Expert Rev Clin Pharmacol. 2019 Oct;12(10):973-980. doi: 10.1080/17512433.2019.1670059. Epub 2019 Sep 29.
3
Bullous pemphigoid.大疱性类天疱疮
An Bras Dermatol. 2019 Mar-Apr;94(2):133-146. doi: 10.1590/abd1806-4841.20199007. Epub 2019 May 9.
4
Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.免疫接种后和病毒感染后大疱性类天疱疮三例报告：探寻确切诱因
BMC Pediatr. 2017 Feb 23;17(1):60. doi: 10.1186/s12887-017-0813-0.
5
Viruses and pemphigus: an intriguing never-ending story.病毒与天疱疮：一个引人入胜的无尽故事。
Dermatology. 2014;229(4):310-5. doi: 10.1159/000365845. Epub 2014 Nov 20.
Zotero 插件